282
Views
1
CrossRef citations to date
0
Altmetric
Patent Evaluations

Evaluation of WO-2013040863, WO-2013041042 and WO-2013043962. Selective JAK1 inhibitors based on a 3-aminopyrazole-4-carboxamide scaffold

, MBA PhD

Bibliography

  • Ihle JN. The Janus kinase family and signaling through members of the cytokine receptor superfamily. Proc Soc Exp Biol Med 1994;206(3):268-72
  • O'Shea JJ, Kontzias A, Yamaoka K, et al. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis 2013;72(Suppl 2):ii111-15
  • Tam CS, Verstovsek S. Investigational Janus kinase inhibitors. Expert Opin Investig Drugs 2013;22(6):687-99
  • Menet CJ, Rompaey LV, Geney R. Advances in the discovery of selective JAK inhibitors. Prog Med Chem 2013;52:153-223
  • Norman P. Selective JAK1 inhibitor and selective Tyk2 inhibitor patents. Expert Opin Ther Pat 2012;22(10):1233-49
  • Menet C. First selective JAK1 inhibitor: GLPG0634 from hit to Proof of concept at protein kinase 2012. Cambridge. 2012. Available from: http://www.soci.org/News/∼/media/Files/Conference%20Downloads/Protein%20Kinase%202012/Christel_Menet_Presentation.ashx
  • Galapagos NV. 5-phenyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl carboxamides as jak inhibitors. WO2010149769; 2010
  • Galapagos NV. [1, 2, 4]triazolo[1, 5-a] pyridines as jak inhibitors. WO2010010184; 2010
  • Galapagos NV. Novel compound useful for the treatment of degenerative and inflammatory diseases. WO2012146657; 2012
  • Incyte Corp. Processes and intermediates for making a jak inhibitor. WO2013036611; 2013
  • Incyte Corp. Cyclohexyl azetidine derivatives as jak inhibitors. WO2013026025; 2013
  • Pfizer, Inc. Pyrrolo[2,3-d]pyrimidine compounds. WO2011075334; 2011
  • Pfizer, Inc. Pyrrolo[2,3-d]pyrimidine compounds. WO2011045702; 2011
  • Pfizer, Inc. Pyrrolo[2,3-d]pyrimidine urea compounds as jak inhibitors. WO2011097087; 2011
  • Advinus Therapeutics Ltd. Substituted fused tricyclic compounds, compositions and medicinal applications thereof. WO2012127506; 2012
  • Zak M, Hurley CA, Ward SI, et al. Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2. J Med Chem 2013;56(11):4764-85
  • Merck Sharp & Dohme Corp. Inhibitors of janus kinases. WO2010014453; 2010
  • Merck Sharp & Dohme Corp. Azaindoles as janus kinase inhibitors. WO2011137022; 2011
  • Merck Sharp & Dohme Corp. Cyanomethylpyrazole carboxamides as janus kinase inhibitors. WO2013043962; 2013
  • Merck Sharp & Dohme Corp. Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors. WO2013040863; 2013
  • Merck Sharp & Dohme Corp. Pyrazole carboxamides as janus kinase inhibitors. WO2013041042; 2013
  • Tundwal K, Alam R. JAK and Src tyrosine kinase signaling in asthma. Front Biosci 2012;17:2107-21
  • Guntur VP, Reinero CR. The potential use of tyrosine kinase inhibitors in severe asthma. Curr Opin Allergy Clin Immunol 2012;12(1):68-75
  • Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors. WO2013085802; 2013

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.